Loading...

GTx

DB:GTU1
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GTU1
DB
$28M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • GTx has significant price volatility in the past 3 months.
GTU1 Share Price and Events
7 Day Returns
-6.5%
DB:GTU1
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-92.5%
DB:GTU1
-9.2%
DE Biotechs
-6.7%
DE Market
GTU1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GTx (GTU1) -6.5% -13.5% 16.8% -92.5% -83.1% -90.1%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • GTU1 underperformed the Biotechs industry which returned -9.2% over the past year.
  • GTU1 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
GTU1
Industry
5yr Volatility vs Market
Related Companies

GTU1 Value

 Is GTx undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for GTx. This is due to cash flow or dividend data being unavailable. The share price is €0.995.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GTx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GTx's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GTU1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.65
NasdaqCM:GTXI Share Price ** NasdaqCM (2019-04-18) in USD $1.15
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GTx.

DB:GTU1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:GTXI Share Price ÷ EPS (both in USD)

= 1.15 ÷ -1.65

-0.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GTx is loss making, we can't compare its value to the Europe Biotechs industry average.
  • GTx is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does GTx's expected growth come at a high price?
Raw Data
DB:GTU1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.7x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GTx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GTx's assets?
Raw Data
DB:GTU1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.09
NasdaqCM:GTXI Share Price * NasdaqCM (2019-04-18) in USD $1.15
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:GTU1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:GTXI Share Price ÷ Book Value per Share (both in USD)

= 1.15 ÷ 1.09

1.06x

* Primary Listing of GTx.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GTx is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess GTx's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GTx has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GTU1 Future Performance

 How is GTx expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GTx expected to grow at an attractive rate?
  • Unable to compare GTx's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare GTx's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare GTx's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:GTU1 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GTU1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GTU1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 0 -9 1
DB:GTU1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -39 -38
2018-09-30 -39 -42
2018-06-30 -35 -41
2018-03-31 -29 -38
2017-12-31 -23 -30
2017-09-30 -19 -28
2017-06-30 -22 -26
2017-03-31 -21 -26
2016-12-31 -21 -18
2016-09-30 -21 -14
2016-06-30 -19 28
2016-03-31 -20 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if GTx is high growth as no earnings estimate data is available.
  • Unable to determine if GTx is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GTU1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from GTx Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GTU1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31 -0.36 -0.36 -0.36 1.00
DB:GTU1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.65
2018-09-30 -1.86
2018-06-30 -1.99
2018-03-31 -1.99
2017-12-31 -1.75
2017-09-30 -1.75
2017-06-30 -1.71
2017-03-31 -1.74
2016-12-31 -1.22
2016-09-30 -1.00
2016-06-30 1.96
2016-03-31 -1.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GTx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess GTx's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GTx has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GTU1 Past Performance

  How has GTx performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GTx's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GTx does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare GTx's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GTx's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GTx's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GTx Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GTU1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -38.42 9.39
2018-09-30 -42.28 9.53
2018-06-30 -41.35 9.99
2018-03-31 -37.74 9.79
2017-12-31 -30.44 9.19
2017-09-30 -28.03 8.98
2017-06-30 -26.44 8.68
2017-03-31 -26.08 8.68
2016-12-31 -17.72 8.71
2016-09-30 -14.09 8.51
2016-06-30 27.69 8.23
2016-03-31 -14.21 8.24
2015-12-31 -18.70 8.23
2015-09-30 -30.02 8.57
2015-06-30 -69.82 8.13
2015-03-31 -32.81 8.96
2014-12-31 -39.41 9.48
2014-09-30 -32.66 9.88
2014-06-30 -36.66 10.77
2014-03-31 -38.52 10.62
2013-12-31 -42.11 11.28
2013-09-30 -44.99 11.05
2013-06-30 -43.05 11.56
2013-03-31 -41.48 11.28
2012-12-31 -40.93 10.85
2012-09-30 0.00 -41.71 11.29
2012-06-30 -2.87 -44.61 8.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if GTx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if GTx has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GTx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GTx's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GTx has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GTU1 Health

 How is GTx's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GTx's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GTx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GTx has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GTx's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • GTx has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GTx Company Filings, last reported 3 months ago.

DB:GTU1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 26.11 0.00 28.46
2018-09-30 30.96 0.00 38.07
2018-06-30 39.84 0.00 45.72
2018-03-31 24.75 0.00 32.14
2017-12-31 38.26 0.00 43.90
2017-09-30 46.57 0.00 53.63
2017-06-30 8.48 0.00 11.36
2017-03-31 14.19 0.00 16.51
2016-12-31 19.89 0.00 21.87
2016-09-30 12.39 0.00 13.44
2016-06-30 18.45 0.00 19.77
2016-03-31 23.69 0.00 24.26
2015-12-31 1.86 0.00 29.26
2015-09-30 4.31 0.00 34.46
2015-06-30 -31.31 0.00 39.43
2015-03-31 15.90 0.00 44.60
2014-12-31 17.83 0.00 49.30
2014-09-30 10.62 0.00 11.54
2014-06-30 15.29 0.00 17.26
2014-03-31 25.09 0.00 27.78
2013-12-31 10.68 0.00 14.73
2013-09-30 16.94 0.00 20.96
2013-06-30 24.76 0.00 31.64
2013-03-31 36.06 0.00 42.22
2012-12-31 47.70 0.00 56.09
2012-09-30 59.91 0.00 47.29
2012-06-30 51.69 0.00 55.93
  • GTx has no debt.
  • GTx has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • GTx has less than a year of cash runway based on current free cash flow.
  • GTx has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.3% each year.
X
Financial health checks
We assess GTx's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GTx has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GTU1 Dividends

 What is GTx's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GTx dividends.
If you bought €2,000 of GTx shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GTx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GTx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GTU1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GTU1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GTx has not reported any payouts.
  • Unable to verify if GTx's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GTx's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GTx has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess GTx's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GTx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GTx has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GTU1 Management

 What is the CEO of GTx's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marc Hanover
COMPENSATION $984,017
AGE 55
TENURE AS CEO 4.2 years
CEO Bio

Mr. Marc S. Hanover, MBA, Co-founded GTX Inc. in September 1997 and has been its Chief Executive Officer since February 2015. Mr. Hanover served as Interim Chief Executive Officer of GTX Inc. from April 3, 2014 to February 2015. He served as President and Chief Operating Officer of GTX Inc from September 1997 to February 2015. He served as Acting Principal Financial Officer of GTX since December 31, 2013 until April 3, 2014. Prior to GTX, Mr. Hanover founded Equity Partners international, Inc., a Private Equity Firm in Memphis, Tennessee and Participated as a founder and Investor in three Healthcare Companies. From 1985 to 1997, he served as Senior Vice President at National Bank of Commerce, (also known as National Commerce Financial Corporation), in Memphis, Tennessee. He has been Director of GTX Inc since April 3, 2014. He served as a Director of GTX Inc. from September 1997 to August 3, 2011. Mr. Hanover holds a B.S. degree in Biology from the University of Memphis and an M.B.A. in Finance from the University of Memphis.

CEO Compensation
  • Marc's compensation has increased whilst company is loss making.
  • Marc's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the GTx management team in years:

4.2
Average Tenure
61
Average Age
  • The tenure for the GTx management team is about average.
Management Team

Rob Wills

TITLE
Executive Chairman
COMPENSATION
$691K
AGE
64
TENURE
4.1 yrs

Marc Hanover

TITLE
Co-Founder
COMPENSATION
$984K
AGE
55
TENURE
4.2 yrs

Henry Doggrell

TITLE
VP, Chief Legal Officer & Secretary
COMPENSATION
$778K
AGE
69
TENURE
17.5 yrs

Jason Shackelford

TITLE
VP of Finance & Accounting
COMPENSATION
$417K
AGE
43
TENURE
5 yrs

Diane Young

TITLE
VP & Chief Medical Officer
COMPENSATION
$801K
AGE
61
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the GTx board of directors in years:

10.9
Average Tenure
64
Average Age
  • The average tenure for the GTx board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Rob Wills

TITLE
Executive Chairman
COMPENSATION
$691K
AGE
64
TENURE
4.1 yrs

Marc Hanover

TITLE
Co-Founder
COMPENSATION
$984K
AGE
55
TENURE
21.6 yrs

Ken Glass

TITLE
Director
COMPENSATION
$108K
AGE
71
TENURE
15.1 yrs

Mike Carter

TITLE
Director
COMPENSATION
$113K
AGE
80
TENURE
12.9 yrs

Kenneth Robinson

TITLE
Director
COMPENSATION
$102K
AGE
63
TENURE
10.9 yrs

Pitt Hyde

TITLE
Lead Director
COMPENSATION
$63K
AGE
75
TENURE
4.2 yrs

Garry Neil

TITLE
Director
COMPENSATION
$86K
AGE
64
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Jul 18 Sell Diane Young Individual 16. Jul 18 16. Jul 18 -2,049 €12.56 €-25,726
26. Jun 18 Buy Robert Wills Individual 26. Jun 18 26. Jun 18 5,000 €14.35 €71,765
22. Jun 18 Sell Henry Doggrell Individual 20. Jun 18 20. Jun 18 -7,351 €16.41 €-120,652
22. Jun 18 Sell Jason Shackelford Individual 20. Jun 18 20. Jun 18 -9,279 €16.41 €-152,296
X
Management checks
We assess GTx's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GTx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GTU1 News

Simply Wall St News

GTU1 Company Info

Description

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company’s SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Details
Name: GTx, Inc.
GTU1
Exchange: DB
Founded: 1997
$24,475,998
24,051,844
Website: http://www.gtxinc.com
Address: GTx, Inc.
175 Toyota Plaza,
7th Floor,
Memphis,
Tennessee, 38103,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM GTXI Common Stock Nasdaq Capital Market US USD 03. Feb 2004
DB GTU1 Common Stock Deutsche Boerse AG DE EUR 03. Feb 2004
Number of employees
Current staff
Staff numbers
21
GTx employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 20:32
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.